April 07, 2020
Philanthropic drug development program seeks to accelerate treatments into human clinical trials
April 7, 2020, CLEVELAND, Ohio USA - The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today issued a transatlantic call for proposals for new treatments, pursuant to its recently announced major initiative to support the global fight against novel Coronavirus and potential future pandemic events. Harrington Discovery Institute (HDI) will provide successful applicants with grant funding and expert guidance and oversight in all aspects of drug/therapeutics development, while taking no rights to intellectual property, which is retained by the award recipient and their institution.
“Through this call we will help move near-term drug programs into human clinical trials and expand the pipeline of earlier stage therapies to address deadly viruses in the future,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair of Cardiovascular Innovation and Professor of Medicine at University Hospitals and Case Western Reserve University.
Through its mission and organizational structure, Harrington Discovery Institute aligns non-profit and for-profit resources to advance breakthrough discoveries into medicines. Using guidance from its scientific and investment advisory boards, HDI selects the most promising scientific discoveries from leading global academic labs and determines where financial and expert drug development resources should be invested to accelerate success. HDI also facilitates clinical trials, new company creation and other commercial partnerships.
“The private sector and philanthropic community have quickly made tremendous strides toward new vaccines and the repurposing of approved drugs. We will complement those programs and add significant value by advancing solutions to treat the complications of the current virus, protect against new viruses and viral subtypes, and accelerate the development of broad spectrum anti-viral agents,” Dr. Stamler said.
HDI will select up to ten projects through the call for proposals and its current portfolio of drugs in development. Awarded projects will run for 12 months, with the possibility of extending the engagement.
Award recipients will receive:
Projects being sought:
Emphasis of call:
Who is eligible?
How to apply:
*Please note this is an accelerated application process and timeline.
We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. It is mandatory to procure user consent prior to running these cookies on your website.